Pembrolizumab (pembro) Monotherapy as First-Line Therapy in Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Results After a Minimum of 34 Months of Follow-up From KEYNOTE-427 Cohort B
Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pembrolizumab (pembro) Monotherapy as First-Line Therapy in Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Results After a Minimum of 34 Months of Follow-up From KEYNOTE-427 Cohort B ### Output: Pembrolizumab